Biotron (ASX:BIT) has announced that its lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute in the US. …
Latest Video
New Stories
-
That is $20 million for new PBS listings every week for five years
December 8, 2021 - - Latest News -
Dr Brendan Shaw - Australians now understand there is a 'queue' for new health technologies
December 8, 2021 - - Podcast -
Daily updates on COVID-19 vaccine - 8 December 2021
December 8, 2021 - - COVID-19 -
Value of Australian company Neuren surges on late-stage trial result
December 8, 2021 - - Latest News -
Closing the gap between public pronouncements and reality
December 7, 2021 - - Latest News -
GSK's Patrick Desbiens looking to support industry push for change
December 7, 2021 - - Latest News -
Daily updates on COVID-19 vaccine - 7 December 2021
December 7, 2021 - - COVID-19